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SUMMARY ∑ Churg-Strauss syndrome (CSS) is a necrotizing small vessel vasculitis characterized
by the presence of asthma, hypereosinophilia and sinusitis. Other common manifestations are pul-
monary infiltrates, skin, gastrointestinal and cardiovascular involvement. Although not a criterion
for the diagnosis of CSS, the presence of antineutrophil cytoplasmic autoantibodies (ANCA) is now
established as being associated with CSS. In this report, a 31-year-old male with a history of diffi-
cult-to-control asthma is presented. It was associated with peripheral and bronchoalveolar eosino-
philia, sinusitis, and high level of ANCA (perinuclear labeling pattern). Clinical manifestations ob-
served at the time of relapses were palpable purpura, erythema nodosum, arthralgia, musculoskeletal
complications, and episcleritis. In spite of vasculitis remission, low doses of steroids to control asthma
were neccessary for 10 years. The aim of this case report is to point to the possibility of CSS in
patients with severe persistent asthma and atypical allergic diathesis.
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Introduction
Churg-Strauss syndrome (CSS) is a systemic vascu-
litis characterized by the presence of asthma, hyper-
eosinophilia, and necrotizing vasculitis with extravascu-
lar eosinophil granulomas. Three phases have been de-
scribed in the natural history of the disease (rhinitis,
asthma, vasculitis), although they do not always occur
successively. Initial reports described CSS as a condition
that is usually highly responsive to corticosteroids1. The
American College of Rheumatology has proposed 6 cri-
teria for CSS classification, 4 being necessary for CSS to
be diagnosed with 85% sensitivity and 99.7% specificity:
asthma, eosinophilia >10%, paranasal sinusitis, pulmonary
infiltrate, histologic proof of vasculitis, and mononeuri-
tis multiplex2.
However, it is well accepted that the lesions described
by Churg and Strauss based on histologic examinations
and postmortem studies not commonly seen on biopsies3
are not specific, and their absence should not serve as a
basis to reject the diagnosis of CSS. Although not a cri-
terion of the diagnosis, the presence of antineutrophil
cytoplasmic autoantibodies (ANCA) is now established
as being associated with it3. A sizable proportion of pa-
tients with CSS require not only steroids but also more
aggressive treatment4-6.. Many centers use treatment pro-
tocols devised for Wegener granulomatosis, i.e. daily oral
or intravenous pulse cyclophosphamide3-5. The value of
cyclophosphamide is limited by its high toxicity, particu-
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larly by its detrimental effects on host defense against
infections, its myelotoxic effects, and oncogenic poten-
tial6-7. Treatments other than corticosteroids and cyclo-
phosphamide are definitely needed.
CSS has to be distinguished from asthma, eosinophilic
pneumonia, and peripheral blood eosinophilia related to
other diseases. These include allergy to molds (particu-
larly Aspergillus fumigatus), allergy to drugs (antibiotics
such as minocycline used to treat acne) and parasitic in-
fection.
Case Report
A 31-year-old man developed rhinitis, sinusitis and
asthma in 1990. He started taking depot steroid therapy
prescribed by his general practitioner. In 1991, tests which
showed strong bronchial hyperreactivity, very prominent
bronchoalveolar eosinophilia, and positive skin test to a
number of allergens (Ambrosia elatior, feathers, tree pol-
len, flour) were done. A few months later, serious wors-
ening of asthma occurred and the patient had to be hos-
pitalized. In the discharge letter, it was stated that a ‘higher
dosage of steroids’ had to be used.
In May 1992, the patient was hospitalized at Sveti
Duh General Hospital, Department of Clinical Immu-
nology and Pulmonology. On admission, he was in a
stable asthmatic condition with normal pulmonary func-
tion tests. Therefore, for the first few days, he was treated
only with salbutamol as needed. He had received his last
depot steroid shot 7 days prior to hospitalization. On the
sixth day of hospitalization, severe bronchial obstruction
developed, with a fall in FEV1 by 55% and VC by 25%
compared to the values measured on admission. PEF had
fallen to 200 l/min (the best personal value was 610 l/min).
Treatment with methylprednisolone at a dose of 40 mg
i.v. and theophylline i.v. was introduced for asthma exac-
erbation. The dose of steroids was reduced to 20 mg orally
after three days and inhaled beclomethasone 600 µg daily
added on. As the dosage of systemic steroid was further
reducing, the patient’s condition worsened two weeks
later, and methylprednisolone was increased to 20 mg
orally daily.
Laboratory findings showed a very high level of total
IgE (>1000 kU/L) and positive skin test to some allergens
but negative specific IgE by RAST (Dermatophagoides
pteronyssinus, milk, cat, dog, Ambrosia elatior). Tuberculin
test was hyperreactive (18×18 mm). Absolute peripheral
blood eosinophil count of 1.27x109/l and sputum eosino-
philia of 80% were detected. ANCA were positive in di-
lution up to 1:1024. CSS was considered, based on the
clinical features and laboratory findings, and additional
tests were performed to assess the possible affection of
other organ systems (peripheral nerves, skin, nose, kid-
neys). The results showed that the disease was limited to
the respiratory system only. Methylprednisolone 20 mg
orally together with topical steroids (1000 µg/day) led to
remission of the disease, with a very good eosinopenic
response (absolute eosinophil count dropped from
1.27x109 to 0.28x109). The patient was discharged from
the hospital in a stable asthma condition. After 4 months
of disease improvement and stable asthma condition, ta-
pering of oral steroids and maintaining of only inhaled
ones were tried. However, the patient’s condition seriously
worsened 10 days later; circulating eosinophil count in-
creased to 1.2x109, eosinophil percentage in sputum to
37%, and pulmonary function tests deteriorated seriously.
Treatment with methylprednisolone at a dose of 40 mg
intravenously started. The dosage of 20 mg orally daily
continued after a week, along with salbutamol and topi-
cal steroids. All laboratory findings and clinical param-
eters normalized, and the patient was discharged on 1200
µg inhaled beclomethasone and 16 mg oral methylpred-
nisolone daily. In January 1993, ANCA were still positive,
but in dilution of 1:16, circulating eosinophils were nor-
mal (0.04x109 and 0.2x109), but pulmonary eosinophilia
was considerable (percentage of eosinophils in sputum was
80%). Two months later, the proportion of eosinophils in
sputum was reduced to 12%, eosinophils completely dis-
appeared from nasal swab, and ANCA titer became nega-
tive. In May 1993, bronchoalveolar eosinophilia disap-
peared as well, and pulmonary function tests were com-
pletely normal.
During 1994, the patient did not present for control
check-up. In the meantime, he continued taking 16 mg
of methylprednisolone orally daily and excluded the in-
haled ones. At the beginning of 1995, the patient exhib-
ited clear signs of iatrogenic Cushing syndrome. Serum
cortisol levels were below normal, densitometry showed
moderate spinal osteopenia. In order to taper systemic
steroids, the patient was hospitalized.  Immediately after
the corticosteroid dosage was reduced (with continued
inhaled steroid treatment), the patient developed morn-
ing asthma attacks. On day 7, marked deterioration with
serious obstruction of ventilation occurred (decrease of
FEV1 from 70% to 31%). Upon the introduction of me-
thylprednisolone, 24 mg daily, pulmonary function im-
proved (FEV1 66%). Bronchoalveolar eosinophilia flared
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up again (percentage of eosinophils in sputum was 72%),
eosinophils increased from 0.04x109 to 0.65x109. Serum
ANCA titer was negative.
In 1997, cataract developed on both eyes and the pa-
tient underwent an operation. Atrophic skin changes ap-
peared on both legs and striae disseminated. Erythema
nodosum appeared on the legs, and palpable purpura on
the chest and back. A short course of cyclophosphamide
was introduced.
After remission of the signs of vasculitis, we tried to
reduce the systemic corticosteroid dosage several times
until 1999, but every attempt resulted in serious deterio-
ration of ventilation function.
In March 1999, a decision was made to initiate treat-
ment with montelukast, a leukotriene receptor antagonist,
at a dose of 10 mg daily in the evening. The goal of the
treatment was to maintain stable asthma condition while
tapering the dose of systemic steroids. After four months
of treatment, the patient reported reduced methylpred-
nisolone dosage to 12 mg daily (previously, minimum
dosage was 16 mg daily). He was taking salbutamol as
needed only. Immunological, functional and routine labo-
ratory parameters were normal. Peripheral blood and
bronchoalveolar eosinophilia were absent. The signs of
iatrogenic Cushing syndrome were still present, but there
were no signs of systemic vasculitis activity.
Discussion
CSS is distinguished from other systemic vasculiti-
des by the presence of asthma. Involvement of the myo-
cardium, peripheral nerves, gastrointestinal tract, and
skin is common. Perinuclear ANCA, present in most
patients, should be considered as a major diagnostic cri-
terion but have not proven useful for follow-up pur-
poses8. Glucocorticoids have largely improved patient
outcome in this disorder, and continue to be the basis of
treatment. When control of the inflammatory disease
has been achieved, an alternate-day regimen should be
preferred whenever possible in order to reduce adverse
events9. The physician should always be vigilant to de-
tect infection, the manifestation of which may be clini-
cally indistiguishable from that of vasculitis. Antileu-
kotriene drugs are new therapeutic agents that have re-
cently been introduced for the treatment of asthma10.
Several cases of eosinophilic conditions including CSS
have been reported to be associated with zafirlukast, a
cystenyl leukotriene antagonist11.
We present a 31-year-old man with difficult-to-con-
trol asthma and rhinosinusitis, which were the prodromal
phase of CSS. After clinical recovery from vasculitis, sys-
temic steroids in a dose of 16-20 mg daily were required
for 10 years to control asthma. In order to diminish the
severe signs of Cushing syndrome, repeated attempts to
reduce the dose of oral steroid were made. The attempts
always resulted in severe asthma exacerbation and deci-
sion was made to initiate the treatment with montelukast
for tapering the dose of corticosteroids12,13. After approxi-
mately four months, the patient could reduce methylpred-
nisolone to 12 mg daily, without the need of dosage in-
crease on any of the days.
According to clinical and laboratory findings, the pa-
tient had CSS. Inhalation steroids could not control his
asthma. The leukotriene receptor antagonist enabled re-
duction of the dose of systemic steroids and control of
asthma symptoms14. At the same time, it did not induce
relapse of the underlying autoimmune disease.
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Saæetak
CHURG-STRAUSSOV SINDROM: PRIKAZ SLU»AJA
A. StipiÊ-MarkoviÊ, J. StipiÊ, M. CrnËeviÊ-Urek i V. Crnek-Kunstelj
Churg-Straussov sindrom (CSS) je granulomatozni vaskulitis posredovan antineutrofilnim citoplazmatskim
autoantitijelima perinuklearne fluorescencije (P-ANCA). OËituje se kliniËkim simptomima ustrajne astme i sinusitisa
uz izraæenu eozinofiliju, πto kod progredirajuÊih oblika bolesti prethodi migrirajuÊim pluÊnim infiltratima uz izvanpluÊne
pojavnosti na perifernim æivcima, koæi, srediπnjem æivËanom, probavnom i krvoæilnom sustavu. Prikazujemo bolesnika
s CSS koji se oËitovao teπkom ustrajnom astmom, perifernom i tkivnom eozinofilijom, sinusitisom i izrazito  visokim
titrom P-ANCA. Kontrola astme postignuta je tek nakon 10-godiπnje steroidne terapije uz mnogobrojne nuspojave.
Cilj prikaza je upozoriti na moguÊnost CSS kod teæih oblika astme i ukazati na moguÊnost autoimunih pojavnosti u
bolesnika s atopijskom konstitucijom.
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